Landrum Lisa M, Lanneau Grainger S, Skaggs Valerie J, Gould Natalie, Walker Joan L, McMeekin D Scott, Gold Michael A
Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, Oklahoma University Health Sciences Center, PO Box 26901, WP2410, Oklahoma City, OK 73190, USA.
Gynecol Oncol. 2007 Sep;106(3):521-5. doi: 10.1016/j.ygyno.2007.04.029. Epub 2007 May 31.
Patients with vulvar cancer were stratified into risk groups for survival based on surgicopathologic findings from a prospective study conducted by the Gynecologic Oncology Group from 1977-1984. The purpose of this study is to reassess these risk groups in patients treated in an era of contemporary management.
Patients with vulvar carcinoma were identified from 1990-2005 for retrospective analysis. Charts were abstracted for clinical, histopathologic and surgical data, and patients stratified into four risk groups for survival based on the clinical size of tumor and extent of lymph node metastasis. Univariate and multivariate characteristics were evaluated and 5-year survival determined by Kaplan-Meier method.
175 patients were identified that underwent surgical management with a median age at diagnosis of 59.9 years. Stage distribution included: I (n=89, 51%), II (n=53, 30%), III (n=29, 17%), and IV (n=4, 2%). Stratification into risk groups included: minimal (n=89, 51%), low (n=69, 40%), intermediate (n=11, 6%), and high (n=6; 3%). The survival rate was 100%, 97%, 82% and 100%, respectively, at median follow-up of 54.5 months. Comparatively, the survival rates for historic groups were 97.9%, 87.4%, 74.8% and 29.0%. Using multivariate analysis, age (p=0.04) and lymph node metastasis (p=0.009) were predictive of survival.
Survival among the minimal and low risk groups is preserved in spite of less radical surgery. 5-year survival rate for intermediate and high risk patients also appears to be improved. This is likely a result of advancement in adjuvant chemo-radiation and a younger patient population that presents with less advanced disease.
根据妇科肿瘤学组1977 - 1984年进行的一项前瞻性研究的手术病理结果,将外阴癌患者分为不同的生存风险组。本研究的目的是在当代治疗时代重新评估这些风险组。
确定1990 - 2005年的外阴癌患者进行回顾性分析。提取病历中的临床、组织病理学和手术数据,并根据肿瘤的临床大小和淋巴结转移程度将患者分为四个生存风险组。评估单因素和多因素特征,并采用Kaplan - Meier法确定5年生存率。
共确定175例接受手术治疗的患者,诊断时的中位年龄为59.9岁。分期分布包括:I期(n = 89,51%),II期(n = 53,30%),III期(n = 29,17%)和IV期(n = 4,2%)。分为风险组包括:低危(n = 89,51%),低风险(n = 69,40%),中风险(n = 11,6%)和高风险(n = 6;3%)。中位随访54.5个月时,生存率分别为100%、97%、82%和100%。相比之下,历史组的生存率分别为97.9%、87.4%、74.8%和29.0%。多因素分析显示,年龄(p = 0.04)和淋巴结转移(p = 0.009)是生存的预测因素。
尽管手术不够彻底,但低危和低风险组的生存率得以维持。中风险和高风险患者的5年生存率似乎也有所提高。这可能是辅助放化疗进展以及就诊时疾病分期较晚的年轻患者人群减少的结果。